| 2.06 -0.16 (-7.21%) | 11-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.97  |
1-year : | 3.36 |
| Resists | First : | 2.54 |
Second : | 2.88 |
| Pivot price | 2.36 |
|||
| Supports | First : | 2.01 |
Second : | 1.67 |
| MAs | MA(5) : | 2.25 |
MA(20) : | 2.4 |
| MA(100) : | 2.5 |
MA(250) : | 2.8 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 35.9 |
D(3) : | 46.9  |
| RSI | RSI(14): 30.6 |
|||
| 52-week | High : | 3.9 | Low : | 2.01 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ACIU ] has closed below the lower bollinger band by 18.1%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 0.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.31 - 2.33 | 2.33 - 2.34 |
| Low: | 2.17 - 2.19 | 2.19 - 2.2 |
| Close: | 2.19 - 2.22 | 2.22 - 2.24 |
AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically. Leveraging its proprietary SupraAntigen and Morphomer platforms, the company engineers a range of vaccines, antibodies, and small molecules specifically designed to engage with aberrantly folded proteins implicated across various neurodegenerative disorders. Its pipeline features Crenezumab, a humanized, conformation-specific monoclonal antibody currently undergoing a Phase II clinical prevention trial for Alzheimer's disease (AD). Additionally, AC Immune is advancing ACI-24, an anti-Abeta vaccine candidate, which is in Phase II clinical evaluation for AD and has successfully completed a Phase Ib study for Down syndrome. Other key candidates include ACI-35, an anti-Tau vaccine candidate that has finished Phase Ib clinical assessment, and a Tau-positron emission tomography (PET) imaging tracer, also in Phase II development. Furthermore, the company is engaged in the research and development of small molecule inhibitors to prevent Tau aggregation, targeting AD and various NeuroOrphan indications. Early-stage efforts include discovery and preclinical programs for a spectrum of neurodegenerative diseases, encompassing diagnostic agents aimed at TDP-43, alpha-synuclein, and NLRP3. The company maintains strategic partnerships and licensing agreements with key industry players such as Genentech, Inc., Biogen International GmbH, Janssen Pharmaceuticals, Inc., Life Molecular Imaging SA, Eli Lilly and Company, and WuXi Biologics. Founded in 2003, AC Immune S.A. is headquartered in Lausanne, Switzerland.
Fri, 30 Oct 2026
AC Immune SA (ACIU) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada
Thu, 08 Oct 2026
AC Immune (NasdaqGM:ACIU) Stock Forecast & Analyst Predictions - Simply Wall St
Thu, 24 Sep 2026
AC Immune: Buy Continued ACI-7104 Progress, PD, And Pipeline Expansions (NASDAQ:ACIU) - Seeking Alpha
Thu, 24 Sep 2026
H.C. Wainwright reiterates AC Immune stock rating on trial data - Investing.com
Wed, 23 Sep 2026
AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104 - GlobeNewswire
Wed, 23 Sep 2026
AC Immune posts trial data for Parkinson’s drug (ACIU:NASDAQ) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 99 (M) |
| Held by Insiders | 3.918e+007 (%) |
| Held by Institutions | 38 (%) |
| Shares Short | 3,300 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.248e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -246.5 % |
| Operating Margin | 7.8 % |
| Return on Assets (ttm) | -16.1 % |
| Return on Equity (ttm) | -78.6 % |
| Qtrly Rev. Growth | 1 % |
| Gross Profit (p.s.) | 36.9 |
| Sales Per Share | 1.12968e+007 |
| EBITDA (p.s.) | -1.8329e+007 |
| Qtrly Earnings Growth | -0.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -50 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 7.42 |
| Dividend | 0 |
| Forward Dividend | 3.52e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|